Drug Trial Radar · NCT05265923
A Study of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Nov 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Actual
Start
Apr 22, 2022
Primary completion
Oct 31, 2023
Study completion Dec 25, 2023
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, PK, PD and immunogenicity of CM310 in patients with moderate-to-severe atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
CM310Drug
IL-4Rα monoclonal antibody
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects achieving EASI-75 at week 16Time frame: 16 weeks
- Proportion of subjects with IGA score of 0 or 1 and a reduction of IGA score by ≥2 points from baseline at week 16Time frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.